Rapamycin: SA drug development company reaches major milestone
Rapamycin Holdings Inc. has taken its novel compound to human clinical trials, moving closer to regulatory approval of a drug that could fight cancer and other diseases.
Read full article »
Rapamycin manufactures and commercializes sirolimus-based drugs for the treatment of dementia, cancer and autoimmune diseases.
Read more